Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications.
Antonio V SterpettiPublished in: Current atherosclerosis reports (2020)
Systemic inflammatory parameters may be used to follow the clinical outcome in primary and secondary prevention. Medical therapy, both in patients with stable cardiovascular disease, or with acute events, may be tailored taking into consideration the level and course of systemic inflammatory mediators. There is significant space for improvement in primary prevention and in the treatment of patients who have suffered from severe cardiovascular events, paying attention to not only blood pressure and cholesterol levels but also including inflammatory parameters in our clinical analysis. The potential exists to alter the course of atherosclerosis with anti-inflammatory drugs. With increased understanding of the specific mechanisms that regulate the relationship between inflammation and atherosclerosis, new, more effective and specific anti-inflammatory treatment may become available.
Keyphrases
- cardiovascular disease
- cardiovascular events
- oxidative stress
- coronary artery disease
- blood pressure
- anti inflammatory drugs
- anti inflammatory
- drug induced
- healthcare
- liver failure
- type diabetes
- early onset
- respiratory failure
- metabolic syndrome
- stem cells
- heart rate
- adipose tissue
- smoking cessation
- mesenchymal stem cells
- extracorporeal membrane oxygenation
- intensive care unit
- insulin resistance
- aortic dissection